SCN10A and neuropathy, small fiber: Other gain-of-function mutations in SCN10A have been reported and are also associated with painful neuropathy (predominantly small fiber neuropathy) caused by alterations in channel gating that promote neuronal hyperexcitability.[52,53] Currently there are no Nav1.8-specific compounds in clinical testing; however, there are several compounds that have been shown to be efficacious in animals models of inflammatory, and perhaps more surprisingly, neuropathic pain.[54,55]